ist wieder gut zurück gekommen, ein interessanter Wert.
isht.comdirect.de/charts/...ors=0x000000&sSym=PRAN.NAS&hcmask=
Gruß
Soros
isht.comdirect.de/charts/...ors=0x000000&sSym=PRAN.NAS&hcmask=
Gruß
Soros
Top-News
Prana Technology (NASDAQ)
Beiträge:
19
Zugriffe: 4.409 / Heute: 1
Zugriffe: 4.409 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI USA Banks UCITS ETF 1D
Perf. 12M: +70,66%
Xtrackers S&P 500 2x Leveraged Daily Swap UCITS ETF 1C
Perf. 12M: +66,39%
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +61,91%
Xtrackers MSCI USA Communication Services UCITS ETF 1D
Perf. 12M: +53,61%
Xtrackers MSCI World Communication Services UCITS ETF 1C
Perf. 12M: +50,55%
WKN: 753907
Webcast Available for Prana's Presentation at Banc of America 2004 Healthcare Conference
MELBOURNE, Australia - PRNewswire-FirstCall - May 19
MELBOURNE, Australia, May 19 /PRNewswire-FirstCall/ -- Prana Biotechnology Limited today announced that the webcast of founding scientist Dr. Ashley Bush's presentation at the Banc of America 2004 Healthcare Conference on Thursday, May 20, 2004, at 8:00 AM PDT, is available on Prana's corporate website at www.pranabio.com/ under the press release section of the corporate page or on the Banc of America website at www.veracast.com/webcasts/bas/healthcare-2004/id11211327.cfm .
Founding scientists Drs. Rudolph Tanzi and Ashley Bush's theories concerning the interaction between metals and the protein beta-amyloid in the brain are the basis of Prana's treatments for Alzheimer's and other neurodegenerative diseases.
About Prana
Prana is a Melbourne-based biotechnology established in 1997 to commercialize research into Alzheimer's disease and other major age-related degenerative disorders . Prana's technology was discovered by the company's researchers at prominent international institutions including Massachusetts General Hospital at Harvard Medical School, the University of Melbourne and the Mental Health Research Institute in Melbourne. For more information about Prana, please visit www.pranabio.com/
This press release contains "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the Company's business strategy and future plans of operation. Forward-looking statements involve known and unknown risks and uncertainties; both general and specific to the matters discussed in this press release. These and other important factors, including those mentioned in various Securities and Exchange Commission filings made by the Company, may cause the Company's actual results and performance to differ materially from the future results and performance expressed in or implied by such forward-looking statements. The forward-looking statements contained in this press release speak only as of the date hereof and the Company expressly disclaims any obligation to provide public updates, revisions or amendments to any forward-looking statements made herein to reflect changes in the Company's expectations or future events.
Prana Biotechnology Limited
Web site: www.pranabio.com/
Webcast Available for Prana's Presentation at Banc of America 2004 Healthcare Conference
MELBOURNE, Australia - PRNewswire-FirstCall - May 19
MELBOURNE, Australia, May 19 /PRNewswire-FirstCall/ -- Prana Biotechnology Limited today announced that the webcast of founding scientist Dr. Ashley Bush's presentation at the Banc of America 2004 Healthcare Conference on Thursday, May 20, 2004, at 8:00 AM PDT, is available on Prana's corporate website at www.pranabio.com/ under the press release section of the corporate page or on the Banc of America website at www.veracast.com/webcasts/bas/healthcare-2004/id11211327.cfm .
Founding scientists Drs. Rudolph Tanzi and Ashley Bush's theories concerning the interaction between metals and the protein beta-amyloid in the brain are the basis of Prana's treatments for Alzheimer's and other neurodegenerative diseases.
About Prana
Prana is a Melbourne-based biotechnology established in 1997 to commercialize research into Alzheimer's disease and other major age-related degenerative disorders . Prana's technology was discovered by the company's researchers at prominent international institutions including Massachusetts General Hospital at Harvard Medical School, the University of Melbourne and the Mental Health Research Institute in Melbourne. For more information about Prana, please visit www.pranabio.com/
This press release contains "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the Company's business strategy and future plans of operation. Forward-looking statements involve known and unknown risks and uncertainties; both general and specific to the matters discussed in this press release. These and other important factors, including those mentioned in various Securities and Exchange Commission filings made by the Company, may cause the Company's actual results and performance to differ materially from the future results and performance expressed in or implied by such forward-looking statements. The forward-looking statements contained in this press release speak only as of the date hereof and the Company expressly disclaims any obligation to provide public updates, revisions or amendments to any forward-looking statements made herein to reflect changes in the Company's expectations or future events.
Prana Biotechnology Limited
Web site: www.pranabio.com/
so ist der Name korrekt: Prana Biotechnology Ltd - American Depositary Shares
Prana's Senior Scientific Consultant to Take Up Federation Fellowship in Melbourne
MELBOURNE, Australia, Jun 23, 2004 /PRNewswire-FirstCall via COMTEX/ -- Prana
Biotechnology Limited (Nasdaq: PRAN; ASX: PBT) today announced that Dr Ashley
Bush, co-founding scientist and senior scientific consultant to Prana
Biotechnology, has been awarded the highly prestigious Federation Fellowship
from the Australian Research Council to continue, in Australia, his ground-
breaking research into neurodegenerative diseases. Dr Bush will return from
Harvard Medical School to take up the five-year Fellowship at Melbourne's Mental
Health Research Institute (MHRI), which initiated and sponsored his application,
and guaranteed financial, infrastructural and equipment-related support. The
Federation Fellowships are designed to develop and retain " ... world-class
Australian researchers in key positions, and create new ... incentives for the
application of their talents in Australia."
Dr Bush's research, conducted with Professor Rudy Tanzi at Harvard Medical
School, forms the basis of the Prana's technology to treat Alzheimer's disease.
As a result of the Fellowship, Dr Bush will make the Mental Health Research
Institute in Australia his primary research base, while maintaining his close
collaborations around the world by continuing his work on the role of metals in
the brain and their relationship to neurodegenerative diseases, particularly in
Alzheimer's disease.
Executive Chairman of Prana, Geoffrey Kempler, stated, "We are delighted and
applaud the high profile recognition and support of Ashley's skill by the ARC
and the Mental Health Research Institute.
"In our rapidly ageing society, neurodegenerative disorders such as Alzheimer's
and Parkinson's diseases will present a huge medical and economic challenge and
demand novel and powerful science such as Ashley's research into the
interactions between metals and proteins in the brain.
"This Federation Fellowship will lead to a deeper understanding of the basic
mechanisms underlying such disorders, which is likely to improve the treatment
of Alzheimer's disease and other neurodegenerative disorders," concluded Mr
Kempler.
Federation Fellowships, awarded via the Australian Research Council, were
created to develop and retain outstanding research in Australia. The
internationally competitive salary that accompanies each Fellowship makes the
return to Australia by expatriate researchers an attractive proposal.
Prana's MPACs (metal protein attenuating compounds) are chemicals that bind zinc
and copper, and have been shown by Prana to lower the levels of the amyloid beta
protein and the associated toxicity in the brain. A better understanding of
metal-protein interactions in the brain is expected to advance the development
of Prana's MPACs. One of them, PBT-1, has already established proof of concept
of Prana's technology in a successful clinical trial. ends
About Prana Biotechnology Limited
Prana is a Melbourne-based biotechnology established in 1997 to commercialize
research into Alzheimer's disease and other major age-related degenerative
disorders (Nasdaq: PRAN; ASX: PBT). Prana's technology was discovered by the
company's researchers at prominent international institutions including
Massachusetts General Hospital at Harvard Medical School, the University of
Melbourne and the Mental Health Research Institute in Melbourne. For more
information about Prana, please visit www.pranabio.com
About the Mental Health Research Institute (MHRI)
The MHRI is Australia's premier mental health research institute. Our mission is
to discover the causes and improve the diagnosis and treatment of the major
functional psychoses, such as schizophrenia, bipolar disorder and major
depression, and neurodegenerative diseases, such as Alzheimer's Type Dementia.
The Institute's research is multidisciplinary and seeks to integrate basic and
clinical platforms. Comprised of over 90 staff of whom more than 30 are
doctoral, the MHRI is an independent institute (company limited by guarantee),
which has close and productive links with Melbourne and Monash Universities, the
Austin Hospital and related institutes. The Institute is a founding partner of
Neuroscience Victoria and has several links with Industry including Eli Lilly,
Schering AG and Prana. The award of a Federation Fellowship to Ashley Bush
through and at the MHRI will have a major positive impact on the Institute's
science, especially in the area of neurodegenerative disorders.
SOURCE Prana Biotechnology Limited
Dr. As
MELBOURNE, Australia, Jun 23, 2004 /PRNewswire-FirstCall via COMTEX/ -- Prana
Biotechnology Limited (Nasdaq: PRAN; ASX: PBT) today announced that Dr Ashley
Bush, co-founding scientist and senior scientific consultant to Prana
Biotechnology, has been awarded the highly prestigious Federation Fellowship
from the Australian Research Council to continue, in Australia, his ground-
breaking research into neurodegenerative diseases. Dr Bush will return from
Harvard Medical School to take up the five-year Fellowship at Melbourne's Mental
Health Research Institute (MHRI), which initiated and sponsored his application,
and guaranteed financial, infrastructural and equipment-related support. The
Federation Fellowships are designed to develop and retain " ... world-class
Australian researchers in key positions, and create new ... incentives for the
application of their talents in Australia."
Dr Bush's research, conducted with Professor Rudy Tanzi at Harvard Medical
School, forms the basis of the Prana's technology to treat Alzheimer's disease.
As a result of the Fellowship, Dr Bush will make the Mental Health Research
Institute in Australia his primary research base, while maintaining his close
collaborations around the world by continuing his work on the role of metals in
the brain and their relationship to neurodegenerative diseases, particularly in
Alzheimer's disease.
Executive Chairman of Prana, Geoffrey Kempler, stated, "We are delighted and
applaud the high profile recognition and support of Ashley's skill by the ARC
and the Mental Health Research Institute.
"In our rapidly ageing society, neurodegenerative disorders such as Alzheimer's
and Parkinson's diseases will present a huge medical and economic challenge and
demand novel and powerful science such as Ashley's research into the
interactions between metals and proteins in the brain.
"This Federation Fellowship will lead to a deeper understanding of the basic
mechanisms underlying such disorders, which is likely to improve the treatment
of Alzheimer's disease and other neurodegenerative disorders," concluded Mr
Kempler.
Federation Fellowships, awarded via the Australian Research Council, were
created to develop and retain outstanding research in Australia. The
internationally competitive salary that accompanies each Fellowship makes the
return to Australia by expatriate researchers an attractive proposal.
Prana's MPACs (metal protein attenuating compounds) are chemicals that bind zinc
and copper, and have been shown by Prana to lower the levels of the amyloid beta
protein and the associated toxicity in the brain. A better understanding of
metal-protein interactions in the brain is expected to advance the development
of Prana's MPACs. One of them, PBT-1, has already established proof of concept
of Prana's technology in a successful clinical trial. ends
About Prana Biotechnology Limited
Prana is a Melbourne-based biotechnology established in 1997 to commercialize
research into Alzheimer's disease and other major age-related degenerative
disorders (Nasdaq: PRAN; ASX: PBT). Prana's technology was discovered by the
company's researchers at prominent international institutions including
Massachusetts General Hospital at Harvard Medical School, the University of
Melbourne and the Mental Health Research Institute in Melbourne. For more
information about Prana, please visit www.pranabio.com
About the Mental Health Research Institute (MHRI)
The MHRI is Australia's premier mental health research institute. Our mission is
to discover the causes and improve the diagnosis and treatment of the major
functional psychoses, such as schizophrenia, bipolar disorder and major
depression, and neurodegenerative diseases, such as Alzheimer's Type Dementia.
The Institute's research is multidisciplinary and seeks to integrate basic and
clinical platforms. Comprised of over 90 staff of whom more than 30 are
doctoral, the MHRI is an independent institute (company limited by guarantee),
which has close and productive links with Melbourne and Monash Universities, the
Austin Hospital and related institutes. The Institute is a founding partner of
Neuroscience Victoria and has several links with Industry including Eli Lilly,
Schering AG and Prana. The award of a Federation Fellowship to Ashley Bush
through and at the MHRI will have a major positive impact on the Institute's
science, especially in the area of neurodegenerative disorders.
SOURCE Prana Biotechnology Limited
Dr. As
Sell on good news, oder kam der Vortrag nicht gut an?
Prana Biotechnology Presents at the 9th International Conference on Alzheimer's Disease Co-founding scientist to discuss new data on the interaction of cholesterol with beta-amyloid and brain metals
PHILADELPHIA, Jul 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dr. Ashley
Bush, chief scientific consultant and co-founder of Prana Biotechnology Limited
(Nasdaq: PRAN; ASX: PBT) is scheduled to present a lecture tonight at the 9th
International Conference on Alzheimer's Disease and Related Disorders (ICAD), a
specialist international symposium in Philadelphia at the Pennsylvania
Convention Center, Ballroom A/B. The event will commence at 5:30 PM.
Dr. Bush intends to present a lecture entitled "Clioquinol and the Metal-
Protein Attenuating Compounds (MPACs*) in the treatment of Alzheimer's disease"
at a session devoted to the development of therapeutic strategies. Based on the
hypothesis that beta amyloid is a key player in the onset and progression of
Alzheimer's disease, Prana maintains that it is the inappropriate interaction of
beta amyloid with brain metals copper and zinc that leads to the progression
associated with the disease. As part of his remarks, Dr. Bush intends to discuss
how clioquinol detects amyloid pathology in brain tissue and how the drug
arrives at the appropriate biochemical target in living transgenic mice and in
post-mortem tissue from patients with Alzheimer's disease.
Dr. Bush and his co-workers at the University of Melbourne and Massachusetts
General Hospital have developed this theory over 15 years of research. For much
of this time, the research community has been sceptical toward what was a major
departure from the more favoured theories. Invitations to present the MPAC
approach at premier conferences such as ICAD demonstrate the increasing support
for Prana's technology in the Alzheimer's community.
Co-founding Scientist of Prana, Dr. Rudolph E. Tanzi, Professor of Neurology at
Harvard Medical School said, "This conference is regarded as an important event,
not only for scientists and medical practitioners in the industry, but also for
the millions of patients worldwide who have Alzheimer's, This invitation to
speak to international peers about the scientific basis for Prana's MPAC
technology is an indication that our theories have achieved considerable
acceptance."
Also at ICAD, on Wednesday July 21, Dr. Bush is scheduled to give an invited
lecture that will review the basic neuroscience describing the involvement of
brain copper and zinc in Alzheimer pathology. New data is expected to be
presented on the interaction of cholesterol with beta-amyloid and brain metals,
which may play a key role in the sequence of events that leads to dementia. The
possibility that beta-amyloid participates in the functional regulation of
copper levels in health will be discussed.
(*MPACs, or Metal-Protein Attenuating Compounds are compounds that bind metals
to prevent their interactions with proteins.)
International Conference on Alzheimer's Disease (ICAD)
The ICAD is the world's leading forum on dementia research, and provides the
opportunity for more than 5,000 attending researchers to share knowledge and
develop creative new approaches to increasing the understanding of Alzheimer's.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialise research into Alzheimer's
disease and other major age-related degenerative disorders. The company was
incorporated in 1997 and listed on the Australian Stock Exchange in March 2000.
Researchers at prominent international institutions including the University of
Melbourne and Massachusetts General Hospital at Harvard Medical School
discovered Prana's technology.
This press release contains "forward looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 regarding the Company's
business strategy and future plans of operation. Forward-looking statements
involve known and unknown risks and uncertainties; both general and specific to
the matters discussed in this press release. These and other important factors,
including those mentioned in various Securities and Exchange Commission filings
made by the Company, may cause the Company's actual results and performance to
differ materially from the future results and performance expressed in or
implied by such forward-looking statements. The forward-looking statements
contained in this press release speak only as of the date hereof and the Company
expressly disclaims any obligation to provide public updates, revisions or
amendments to any forward-looking statements made herein to reflect changes in
the Company's expectations or future events.
For further information, please visit our web site at www.pranabio.com.
bitte um Meinungen!
Danke
gs
Prana Biotechnology Presents at the 9th International Conference on Alzheimer's Disease Co-founding scientist to discuss new data on the interaction of cholesterol with beta-amyloid and brain metals
PHILADELPHIA, Jul 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dr. Ashley
Bush, chief scientific consultant and co-founder of Prana Biotechnology Limited
(Nasdaq: PRAN; ASX: PBT) is scheduled to present a lecture tonight at the 9th
International Conference on Alzheimer's Disease and Related Disorders (ICAD), a
specialist international symposium in Philadelphia at the Pennsylvania
Convention Center, Ballroom A/B. The event will commence at 5:30 PM.
Dr. Bush intends to present a lecture entitled "Clioquinol and the Metal-
Protein Attenuating Compounds (MPACs*) in the treatment of Alzheimer's disease"
at a session devoted to the development of therapeutic strategies. Based on the
hypothesis that beta amyloid is a key player in the onset and progression of
Alzheimer's disease, Prana maintains that it is the inappropriate interaction of
beta amyloid with brain metals copper and zinc that leads to the progression
associated with the disease. As part of his remarks, Dr. Bush intends to discuss
how clioquinol detects amyloid pathology in brain tissue and how the drug
arrives at the appropriate biochemical target in living transgenic mice and in
post-mortem tissue from patients with Alzheimer's disease.
Dr. Bush and his co-workers at the University of Melbourne and Massachusetts
General Hospital have developed this theory over 15 years of research. For much
of this time, the research community has been sceptical toward what was a major
departure from the more favoured theories. Invitations to present the MPAC
approach at premier conferences such as ICAD demonstrate the increasing support
for Prana's technology in the Alzheimer's community.
Co-founding Scientist of Prana, Dr. Rudolph E. Tanzi, Professor of Neurology at
Harvard Medical School said, "This conference is regarded as an important event,
not only for scientists and medical practitioners in the industry, but also for
the millions of patients worldwide who have Alzheimer's, This invitation to
speak to international peers about the scientific basis for Prana's MPAC
technology is an indication that our theories have achieved considerable
acceptance."
Also at ICAD, on Wednesday July 21, Dr. Bush is scheduled to give an invited
lecture that will review the basic neuroscience describing the involvement of
brain copper and zinc in Alzheimer pathology. New data is expected to be
presented on the interaction of cholesterol with beta-amyloid and brain metals,
which may play a key role in the sequence of events that leads to dementia. The
possibility that beta-amyloid participates in the functional regulation of
copper levels in health will be discussed.
(*MPACs, or Metal-Protein Attenuating Compounds are compounds that bind metals
to prevent their interactions with proteins.)
International Conference on Alzheimer's Disease (ICAD)
The ICAD is the world's leading forum on dementia research, and provides the
opportunity for more than 5,000 attending researchers to share knowledge and
develop creative new approaches to increasing the understanding of Alzheimer's.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialise research into Alzheimer's
disease and other major age-related degenerative disorders. The company was
incorporated in 1997 and listed on the Australian Stock Exchange in March 2000.
Researchers at prominent international institutions including the University of
Melbourne and Massachusetts General Hospital at Harvard Medical School
discovered Prana's technology.
This press release contains "forward looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 regarding the Company's
business strategy and future plans of operation. Forward-looking statements
involve known and unknown risks and uncertainties; both general and specific to
the matters discussed in this press release. These and other important factors,
including those mentioned in various Securities and Exchange Commission filings
made by the Company, may cause the Company's actual results and performance to
differ materially from the future results and performance expressed in or
implied by such forward-looking statements. The forward-looking statements
contained in this press release speak only as of the date hereof and the Company
expressly disclaims any obligation to provide public updates, revisions or
amendments to any forward-looking statements made herein to reflect changes in
the Company's expectations or future events.
For further information, please visit our web site at www.pranabio.com.
bitte um Meinungen!
Danke
gs
Prana presents at 9th International Conference on Alzheimers
Announced by: PBT
Announced on: 20/07/2004 09:41:02
Words: 1002
Status: Not market sensitive (N)
View original PDF
--------------------------------------------------
6 jahre später.
was ist passiert?`gibt es fortschritte?
mfg chris
und...
niemand da^^
:D
na ja nicht si schlimm... habe sie unter $2 auf den Tisch bekomen (heute) und auch nicht gekauft...
war aber einer der besten intarady Charts, die es marktweit heute gab...
bis zum nächsten Mal...
niemand da^^
:D
na ja nicht si schlimm... habe sie unter $2 auf den Tisch bekomen (heute) und auch nicht gekauft...
war aber einer der besten intarady Charts, die es marktweit heute gab...
bis zum nächsten Mal...
in den eurokurs (der bis jetzt noch nicht reagiert hat) zu investieren. korrigiert mich, wenn ich falsch liege.
in den breakout zu investieren...
egal ob in $ oder euro
Verdopplung in 24 Stunden
egal ob in $ oder euro
Verdopplung in 24 Stunden
keine Basher keine Pusher...
traumhafte Umgebung zum verdienen...
in manchen Werten die nur ein Bruchteil davon gehen ist ein Mortsgetöse los und man schlägts ich gegenseitig die Köpfe ein^^
hier ist's schön ruhig... :-)
traumhafte Umgebung zum verdienen...
in manchen Werten die nur ein Bruchteil davon gehen ist ein Mortsgetöse los und man schlägts ich gegenseitig die Köpfe ein^^
hier ist's schön ruhig... :-)
der gesamte freefloat wurde gestern umgewälzt......riecht nach weiter steigenden kursen.
gruß doc
gruß doc
viel glück und viel segen auf all meinen wegen;)
ein pp zu 2,25 zu gewähren.......wo der kurs bei 3,75 stand. solche werte sofort von der wl streichen. vorgestern in der spitze 4,5 jetzt 2,9 tendenz fallend. :(
viel glück und viel segen auf all meinen wegen;)
Es gibt keine neuen Beiträge.
Neueste Beiträge aus dem Prana Biotechnology ADR Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
3 | 41 | Der Alzheimer Thread! | geldschneider | maurer0229 | 03.05.23 14:07 | |
| 2 | 107 | Die schöne PRANA | buran | buran | 25.04.21 01:09 | |
| 2 | 149 | Führend in Alzheimer Forschung! PRANA Biotech. | geldschneider | geldschneider | 24.04.21 23:59 | |
| 18 | Prana Technology (NASDAQ) | soros | dr.soldberg | 24.03.11 16:40 | ||
| Mögliche Revolution in der Alzheimer-Forschung? | Geselle | 15.05.03 17:28 |
